

# Won Gu Kim

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6417387/publications.pdf>

Version: 2024-02-01

200  
papers

5,341  
citations

76326

40  
h-index

128289

60  
g-index

203  
all docs

203  
docs citations

203  
times ranked

5011  
citing authors

#	ARTICLE	IF	CITATIONS
1	Limitations of fine-needle aspiration and core needle biopsies in the diagnosis of tall cell variant of papillary thyroid carcinoma. <i>Clinical Endocrinology</i> , 2023, 98, 110-116.	2.4	1
2	Lenvatinib Compared with Sorafenib as a First-Line Treatment for Radioactive Iodine-Refractory, Progressive, Differentiated Thyroid Carcinoma: Real-World Outcomes in a Multicenter Retrospective Cohort Study. <i>Thyroid</i> , 2023, 33, 91-99.	4.5	17
3	Effect of TSH levels during active surveillance of PTMC according to age. <i>Endocrine-Related Cancer</i> , 2022, 29, 191-200.	3.1	7
4	Comparison of <sup>99m</sup> Tc Perchnetate Thyroid Uptake Rates by Gamma Probe and Gamma Camera Methods for Differentiating Graves' Disease and Thyroiditis. <i>Nuclear Medicine and Molecular Imaging</i> , 2022, 56, 42-51.	1.0	5
5	Effects of dabrafenib and erlotinib combination treatment on anaplastic thyroid carcinoma. <i>Endocrine-Related Cancer</i> , 2022, 29, 307-319.	3.1	7
6	Graves' disease diagnosed in remnant thyroid after lobectomy for thyroid cancer. <i>PLoS ONE</i> , 2022, 17, e0265332.	2.5	0
7	Immunoglobulin G4-Related Thyroid Disease: A Single-Center Experience and Literature Review. <i>Endocrinology and Metabolism</i> , 2022, 37, 312-322.	3.0	2
8	Immune Profiling of Advanced Thyroid Cancers Using Fluorescent Multiplex Immunohistochemistry. <i>Thyroid</i> , 2021, 31, 61-67.	4.5	17
9	Real-world experience of lenvatinib in patients with advanced anaplastic thyroid cancer. <i>Endocrine</i> , 2021, 71, 427-433.	2.3	14
10	Interobserver Reproducibility in Sonographic Measurement of Diameter and Volume of Papillary Thyroid Microcarcinoma. <i>Thyroid</i> , 2021, 31, 452-458.	4.5	18
11	Mitofusin-2 modulates the epithelial to mesenchymal transition in thyroid cancer progression. <i>Scientific Reports</i> , 2021, 11, 2054.	3.3	16
12	Genetic Profiles of Aggressive Variants of Papillary Thyroid Carcinomas. <i>Cancers</i> , 2021, 13, 892.	3.7	15
13	Gender-Dependent Reference Range of Serum Calcitonin Levels in Healthy Korean Adults. <i>Endocrinology and Metabolism</i> , 2021, 36, 365-373.	3.0	5
14	Mutation Profile of Aggressive Pheochromocytoma and Paraganglioma with Comparison of TCGA Data. <i>Cancers</i> , 2021, 13, 2389.	3.7	7
15	Mutational Profile of Metastatic Pheochromocytoma and Paraganglioma. <i>Journal of the Endocrine Society</i> , 2021, 5, A71-A71.	0.2	0
16	SHMT2 expression as a diagnostic and prognostic marker for thyroid cancer. <i>Endocrine Connections</i> , 2021, 10, 630-636.	1.9	14
17	Tumor Volume Doubling Time in Active Surveillance of Papillary Thyroid Microcarcinoma: A Multicenter Cohort Study in Korea. <i>Thyroid</i> , 2021, 31, 1494-1501.	4.5	17
18	Clinical implications of age and excellent response to therapy in patients with high-risk differentiated thyroid carcinoma. <i>Clinical Endocrinology</i> , 2021, 95, 882-890.	2.4	4

#	ARTICLE	IF	CITATIONS
19	Active Surveillance as an Effective Management Option for Low-Risk Papillary Thyroid Microcarcinoma. <i>Endocrinology and Metabolism</i> , 2021, 36, 717-724.	3.0	3
20	Clinicopathological Characteristics and Disease-Free Survival in Patients with H <sup>14</sup> rthle Cell Carcinoma: A Multicenter Cohort Study in South Korea. <i>Endocrinology and Metabolism</i> , 2021, 36, 1078-1085.	3.0	5
21	Death-Associated Protein Kinase 1 Inhibits Progression of Thyroid Cancer by Regulating Stem Cell Markers. <i>Cells</i> , 2021, 10, 2994.	4.1	4
22	Mutation in Genes Encoding Key Functional Groups Additively Increase Mortality in Patients with BRAFV600E-Mutant Advanced Papillary Thyroid Carcinoma. <i>Cancers</i> , 2021, 13, 5846.	3.7	7
23	Modified risk stratification based on cervical lymph node metastases following lobectomy for papillary thyroid carcinoma. <i>Clinical Endocrinology</i> , 2020, 92, 358-365.	2.4	4
24	Prognostic role of the lymphocyte-to-monocyte ratio for clinical outcomes of patients with progressive radioiodine-refractory differentiated thyroid carcinoma treated by sorafenib. <i>Clinical Endocrinology</i> , 2020, 92, 71-76.	2.4	12
25	Estimating the Growth Rate of Lung Metastases in Differentiated Thyroid Carcinoma: Response Evaluation Criteria in Solid Tumors or Doubling Time?. <i>Thyroid</i> , 2020, 30, 418-424.	4.5	3
26	Long-term clinical outcomes of papillary thyroid carcinoma patients with biochemical incomplete response. <i>Endocrine</i> , 2020, 67, 623-629.	2.3	14
27	High Phosphoglycerate Dehydrogenase Expression Induces Stemness and Aggressiveness in Thyroid Cancer. <i>Thyroid</i> , 2020, 30, 1625-1638.	4.5	17
28	Dsg2-mediated c-Met activation in anaplastic thyroid cancer motility and invasion. <i>Endocrine-Related Cancer</i> , 2020, 27, 601-614.	3.1	9
29	Genetic profile of advanced thyroid cancers in relation to distant metastasis. <i>Endocrine-Related Cancer</i> , 2020, 27, 285-293.	3.1	22
30	Steroid receptor coactivator-3 as a target for anaplastic thyroid cancer. <i>Endocrine-Related Cancer</i> , 2020, 27, 209-220.	3.1	11
31	Quality of Life in Patients with Papillary Thyroid Microcarcinoma According to Treatment: Total Thyroidectomy with or without Radioactive Iodine Ablation. <i>Endocrinology and Metabolism</i> , 2020, 35, 115.	3.0	10
32	Unmet Clinical Needs in the Treatment of Patients with Thyroid Cancer. <i>Endocrinology and Metabolism</i> , 2020, 35, 14.	3.0	10
33	Modification of the Tumor-Node-Metastasis Staging System for Differentiated Thyroid Carcinoma by Considering Extra-Thyroidal Extension and Lateral Cervical Lymph Node Metastasis. <i>Endocrinology and Metabolism</i> , 2020, 35, 149.	3.0	5
34	Clinical Implication of World Health Organization Classification in Patients with Follicular Thyroid Carcinoma in South Korea: A Multicenter Cohort Study. <i>Endocrinology and Metabolism</i> , 2020, 35, 618-627.	3.0	10
35	Association between urinary sodium levels and iodine status in Korea. <i>Korean Journal of Internal Medicine</i> , 2020, 35, 392-399.	1.7	11
36	Association of Serum Progranulin Levels with Progression of Papillary Thyroid Cancer. <i>Endocrinology and Metabolism</i> , 2020, 35, 288-289.	3.0	1

#	ARTICLE	IF	CITATIONS
37	Clinical Outcomes after Early and Delayed Radioiodine Remnant Ablation in Patients with Low-Risk Papillary Thyroid Carcinoma: Propensity Score Matching Analysis. <i>Endocrinology and Metabolism</i> , 2020, 35, 830-837.	3.0	7
38	MON-494 Quality of Life in Patients with Papillary Thyroid Microcarcinoma According to the Treatment: Total Thyroidectomy Versus Total Thyroidectomy with Radioactive Iodine Remnant Ablation. <i>Journal of the Endocrine Society</i> , 2020, 4, .	0.2	0
39	Clinical Outcomes of N1b Papillary Thyroid Cancer Patients Treated with Two Different Doses of Radioiodine Ablation Therapy. <i>Endocrinology and Metabolism</i> , 2020, 35, 602-609.	3.0	0
40	The value of preoperative antithyroidperoxidase antibody as a novel predictor of recurrence in papillary thyroid carcinoma. <i>International Journal of Cancer</i> , 2019, 144, 1414-1420.	5.1	15
41	Determining Whether Tumor Volume Doubling Time and Growth Rate Can Predict Malignancy After Delayed Diagnostic Surgery of Follicular Neoplasm. <i>Thyroid</i> , 2019, 29, 1418-1424.	4.5	10
42	Comparison of Thyroid Hormones in Euthyroid Athyreotic Patients Treated with Levothyroxine and Euthyroid Healthy Subjects. <i>International Journal of Thyroidology</i> , 2019, 12, 28.	0.1	2
43	Extended Real-World Observation of Patients Treated with Sorafenib for Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma and Impact of Lenvatinib Salvage Treatment: A Korean Multicenter Study. <i>Thyroid</i> , 2019, 29, 1804-1810.	4.5	17
44	Clinical Significance of Gross Invasion of Strap Muscles in Patients With 1- to 4-cm-Sized Papillary Thyroid Carcinoma Undergoing Lobectomy. <i>Annals of Surgical Oncology</i> , 2019, 26, 4466-4471.	1.5	10
45	Sex-Dependent Association between Weight Change and Thyroid Dysfunction: Population-Level Analysis Using the Korean National Health and Nutrition Examination Survey. <i>European Thyroid Journal</i> , 2019, 8, 202-207.	2.4	3
46	Active Surveillance of Papillary Thyroid Microcarcinoma: Where Do We Stand?. <i>European Thyroid Journal</i> , 2019, 8, 298-306.	2.4	35
47	Impact of tumor-associated macrophages and BRAF <sup>V600E</sup> mutation on clinical outcomes in patients with various thyroid cancers. <i>Head and Neck</i> , 2019, 41, 686-691.	2.0	17
48	Modified Transverse-Vertical Gross Examination: a Better Method for the Detection of Definite Capsular Invasion in Encapsulated Follicular-Patterned Thyroid Neoplasms. <i>Endocrine Pathology</i> , 2019, 30, 106-112.	9.0	10
49	When should antithyroid drug therapy to reduce the relapse rate of hyperthyroidism in Graves' disease be discontinued?. <i>Endocrine</i> , 2019, 65, 348-356.	2.3	14
50	Impact of delayed radioiodine therapy in intermediate-to-high-risk papillary thyroid carcinoma. <i>Clinical Endocrinology</i> , 2019, 91, 449-455.	2.4	9
51	Risk of Malignancy According to the Sub-classification of Atypia of Undetermined Significance and Suspicious Follicular Neoplasm Categories in Thyroid Core Needle Biopsies. <i>Endocrine Pathology</i> , 2019, 30, 146-154.	9.0	13
52	Quality of Life in Patients with Papillary Thyroid Microcarcinoma Managed by Active Surveillance or Lobectomy: A Cross-Sectional Study. <i>Thyroid</i> , 2019, 29, 956-962.	4.5	80
53	Tumor Volume Doubling Time in Active Surveillance of Papillary Thyroid Carcinoma. <i>Thyroid</i> , 2019, 29, 642-649.	4.5	44
54	Low Lymphocyte-to-Monocyte Ratios Are Associated with Poor Overall Survival in Anaplastic Thyroid Carcinoma Patients. <i>Thyroid</i> , 2019, 29, 824-829.	4.5	33

#	ARTICLE	IF	CITATIONS
55	Time trends of thyroglobulin antibody in ablated papillary thyroid carcinoma patients: Can we predict the rate of negative conversion?. <i>Oral Oncology</i> , 2019, 91, 29-34.	1.5	6
56	Recent Trends in the Clinicopathological Features of Thyroid Nodules in Pediatric Patients: A Single Tertiary Center Experience over 25 Years. <i>International Journal of Endocrinology</i> , 2019, 2019, 1-8.	1.5	3
57	Refining the tumor-node-metastasis staging system for individualized treatment of differentiated thyroid carcinoma. <i>Oral Oncology</i> , 2019, 89, 8-13.	1.5	5
58	Tumor Growth Rate Does Not Predict Malignancy in Surgically Resected Thyroid Nodules Classified as Bethesda Category III with Architectural Atypia. <i>Thyroid</i> , 2019, 29, 216-221.	4.5	10
59	Mutational profile of papillary thyroid microcarcinoma with extensive lymph node metastasis. <i>Endocrine</i> , 2019, 64, 130-138.	2.3	15
60	The role of Slit2 as a tumor suppressor in thyroid cancer. <i>Molecular and Cellular Endocrinology</i> , 2019, 483, 87-96.	3.2	18
61	A Relook at the T Stage of Differentiated Thyroid Carcinoma with a Focus on Gross Extrathyroidal Extension. <i>Thyroid</i> , 2019, 29, 202-208.	4.5	37
62	Individualized Follow-Up Strategy for Patients with an Indeterminate Response to Initial Therapy for Papillary Thyroid Carcinoma. <i>Thyroid</i> , 2019, 29, 209-215.	4.5	12
63	Lobectomy Is Feasible for 1â€“4â€“cm Papillary Thyroid Carcinomas: A 10-Year Propensity Score Matched-Pair Analysis on Recurrence. <i>Thyroid</i> , 2019, 29, 64-70.	4.5	45
64	Expression of <i>NF2</i> Modulates the Progression of <i>BRAF</i> <sup>V600E</sup> Mutated Thyroid Cancer Cells. <i>Endocrinology and Metabolism</i> , 2019, 34, 203.	3.0	6
65	Tumour growth rate of follicular thyroid carcinoma is not different from that of follicular adenoma. <i>Clinical Endocrinology</i> , 2018, 88, 936-942.	2.4	10
66	Prognostic Implication of N1b Classification in the Eighth Edition of the Tumor-Node-Metastasis Staging System of Differentiated Thyroid Cancer. <i>Thyroid</i> , 2018, 28, 496-503.	4.5	28
67	Serum thyroid-stimulating hormone levels and smoking status: Data from the Korean National Health and Nutrition Examination Survey. <i>Clinical Endocrinology</i> , 2018, 88, 969-976.	2.4	26
68	<i>BRAF</i> and <i>RAS</i> Mutational Status in Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features and Invasive Subtype of Encapsulated Follicular Variant of Papillary Thyroid Carcinoma in Korea. <i>Thyroid</i> , 2018, 28, 504-510.	4.5	40
69	Tertiary Care Experience of Sorafenib in the Treatment of Progressive Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Korean Multicenter Study. <i>Thyroid</i> , 2018, 28, 340-348.	4.5	42
70	Mechanisms Linking Obesity and Thyroid Cancer Development and Progression in Mouse Models. <i>Hormones and Cancer</i> , 2018, 9, 108-116.	4.9	25
71	Preoperative Clinical and Sonographic Predictors for Lateral Cervical Lymph Node Metastases in Sporadic Medullary Thyroid Carcinoma. <i>Thyroid</i> , 2018, 28, 362-368.	4.5	29
72	Radiofrequency ablation of primary thyroid carcinoma: efficacy according to the types of thyroid carcinoma. <i>International Journal of Hyperthermia</i> , 2018, 34, 611-616.	2.5	48

#	ARTICLE	IF	CITATIONS
73	Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancer. <i>OncImmunity</i> , 2018, 7, e1375642.	4.6	83
74	Influence of coexistent Hashimoto's thyroiditis on the extent of cervical lymph node dissection and prognosis in papillary thyroid carcinoma. <i>Clinical Endocrinology</i> , 2018, 88, 123-128.	2.4	40
75	A Follow-Up Strategy for Patients with an Excellent Response to Initial Therapy for Differentiated Thyroid Carcinoma: Less Is Better. <i>Thyroid</i> , 2018, 28, 187-192.	4.5	17
76	Practical Initial Risk Stratification Based on Lymph Node Metastases in Pediatric and Adolescent Differentiated Thyroid Cancer. <i>Thyroid</i> , 2018, 28, 193-200.	4.5	38
77	Management of Hypertension and Proteinuria after Treatment with Lenvatinib for Radioiodine Refractory Papillary Thyroid Carcinoma: a Case Report. <i>International Journal of Thyroidology</i> , 2018, 11, 78.	0.1	0
78	Clinical Outcomes of Differentiated Thyroid Cancer Patients with Local Recurrence or Distant Metastasis Detected in Old Age. <i>Endocrinology and Metabolism</i> , 2018, 33, 459.	3.0	4
79	Eighth edition of tumor-node-metastasis staging system improve survival predictability for papillary, but not follicular thyroid carcinoma: A multicenter cohort study. <i>Oral Oncology</i> , 2018, 87, 97-103.	1.5	12
80	Active Surveillance of Low-Risk Papillary Thyroid Microcarcinoma: A Multi-Center Cohort Study in Korea. <i>Thyroid</i> , 2018, 28, 1587-1594.	4.5	141
81	Modification of the eight-edition tumor-node-metastasis staging system with N1b for papillary thyroid carcinoma: A multi-institutional cohort study. <i>Oral Oncology</i> , 2018, 86, 48-52.	1.5	6
82	Comparison of Immunohistochemistry and Direct Sanger Sequencing for Detection of the <i>BRAF</i> <sup>V600E</sup> Mutation in Thyroid Neoplasm. <i>Endocrinology and Metabolism</i> , 2018, 33, 62.	3.0	20
83	Association Between Thyroid Dysfunction and Lipid Profiles Differs According to Age and Sex: Results from the Korean National Health and Nutrition Examination Survey. <i>Thyroid</i> , 2018, 28, 849-856.	4.5	20
84	Changes in Serum Thyroglobulin Levels After Lobectomy in Patients with Low-Risk Papillary Thyroid Cancer. <i>Thyroid</i> , 2018, 28, 997-1003.	4.5	63
85	Thyroid Incidentalomas Detected on <sup>18</sup> F-Fluorodeoxyglucose Positron Emission Tomography with Computed Tomography: Malignant Risk Stratification and Management Plan. <i>Thyroid</i> , 2018, 28, 762-768.	4.5	16
86	Prognosis of Differentiated Thyroid Carcinoma with Initial Distant Metastasis: A Multicenter Study in Korea. <i>Endocrinology and Metabolism</i> , 2018, 33, 287.	3.0	34
87	Do aggressive variants of papillary thyroid carcinoma have worse clinical outcome than classic papillary thyroid carcinoma?. <i>European Journal of Endocrinology</i> , 2018, 179, 135-142.	3.7	44
88	Decreasing Disease-Specific Mortality of Differentiated Thyroid Cancer in Korea: A Multicenter Cohort Study. <i>Thyroid</i> , 2018, 28, 1121-1127.	4.5	13
89	Association of KCNJ2 Genetic Variants with Susceptibility to Thyrotoxic Periodic Paralysis in Patients with Graves's Disease. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2017, 125, 75-78.	1.2	5
90	A comparison of lobectomy and total thyroidectomy in patients with papillary thyroid microcarcinoma: a retrospective individual risk factor-matched cohort study. <i>European Journal of Endocrinology</i> , 2017, 176, 371-378.	3.7	81

#	ARTICLE	IF	CITATIONS
91	Features of papillary thyroid microcarcinoma associated with lateral cervical lymph node metastasis. <i>Clinical Endocrinology</i> , 2017, 86, 845-851.	2.4	53
92	Excessive Iodine Intake and Thyrotropin Reference Interval: Data from the Korean National Health and Nutrition Examination Survey. <i>Thyroid</i> , 2017, 27, 967-972.	4.5	48
93	Active Surveillance for Patients With Papillary Thyroid Microcarcinoma: A Single Center's Experience in Korea. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 1917-1925.	3.6	164
94	Clinical Features of Early and Late Postoperative Hypothyroidism After Lobectomy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 1317-1324.	3.6	57
95	Serial Neck Ultrasonographic Evaluation of Changes in Papillary Thyroid Carcinoma During Pregnancy. <i>Thyroid</i> , 2017, 27, 773-777.	4.5	29
96	Clinical outcomes after delayed thyroid surgery in patients with papillary thyroid microcarcinoma. <i>European Journal of Endocrinology</i> , 2017, 177, 25-31.	3.7	40
97	Comparison of the Seventh and Eighth Editions of the American Joint Committee on Cancer/Union for International Cancer Control Tumor-Node-Metastasis Staging System for Differentiated Thyroid Cancer. <i>Thyroid</i> , 2017, 27, 1149-1155.	4.5	83
98	Preoperative clinicopathological characteristics of patients with solitary encapsulated follicular variants of papillary thyroid carcinomas. <i>Journal of Surgical Oncology</i> , 2017, 116, 746-755.	1.7	12
99	Lack of Efficacy of Radioiodine Remnant Ablation for Papillary Thyroid Microcarcinoma: Verification Using Inverse Probability of Treatment Weighting. <i>Annals of Surgical Oncology</i> , 2017, 24, 2596-2602.	1.5	17
100	Changes in standardized mortality rates from thyroid cancer in Korea between 1985 and 2015: Analysis of Korean national data. <i>Cancer</i> , 2017, 123, 4808-4814.	4.1	23
101	Dynamic Risk Stratification in Stage I Papillary Thyroid Cancer Patients Younger Than 45 Years of Age. <i>Thyroid</i> , 2017, 27, 1400-1407.	4.5	12
102	Vitamin D deficiency affects thyroid autoimmunity and dysfunction in iodine-replete area: Korea national health and nutrition examination survey. <i>Endocrine</i> , 2017, 58, 332-339.	2.3	20
103	Thyrotropin Suppressive Therapy for Low-Risk Small Thyroid Cancer: A Propensity Score-Matched Cohort Study. <i>Thyroid</i> , 2017, 27, 1164-1170.	4.5	46
104	Age-specific reference interval of serum TSH levels is high in adolescence in an iodine excess area: Korea national health and nutrition examination survey data. <i>Endocrine</i> , 2017, 57, 445-454.	2.3	13
105	Optimal cut-off age in the TNM Staging system of differentiated thyroid cancer: is 55 years better than 45 years?. <i>Clinical Endocrinology</i> , 2017, 86, 438-443.	2.4	43
106	Initial Size of Metastatic Lesions Is Best Prognostic Factor in Patients with Metastatic Differentiated Thyroid Carcinoma Confined to the Lung. <i>Thyroid</i> , 2017, 27, 49-58.	4.5	14
107	Dynamic Risk Stratification for Predicting Recurrence in Patients with Differentiated Thyroid Cancer Treated Without Radioactive Iodine Remnant Ablation Therapy. <i>Thyroid</i> , 2017, 27, 524-530.	4.5	74
108	Serum vitamin D3 levels are not associated with thyroid cancer prevalence in euthyroid subjects without autoimmune thyroid disease. <i>Korean Journal of Internal Medicine</i> , 2017, 32, 102-108.	1.7	19

#	ARTICLE	IF	CITATIONS
109	Disease-Specific Mortality of Differentiated Thyroid Cancer Patients in Korea: A Multicenter Cohort Study. <i>Endocrinology and Metabolism</i> , 2017, 32, 434.	3.0	31
110	Response: Thyroid Stimulating Hormone Reference Range and Prevalence of Thyroid Dysfunction in the Korean Population: Korea National Health and Nutrition Examination Survey 2013 to 2015 ( <i>Endocrinol Metab</i> 2017;32:106-14, Won Gu Kim et al.). <i>Endocrinology and Metabolism</i> , 2017, 32, 304.	3.0	1
111	Thyroid Stimulating Hormone Reference Range and Prevalence of Thyroid Dysfunction in the Korean Population: Korea National Health and Nutrition Examination Survey 2013 to 2015. <i>Endocrinology and Metabolism</i> , 2017, 32, 106.	3.0	84
112	Myxoid and Sarcomatoid Variants of Adrenocortical Carcinoma: Analysis of Rare Variants in Single Tertiary Care Center. <i>Journal of Korean Medical Science</i> , 2017, 32, 764.	2.5	13
113	Growth Kinetics of Macronodular Lung Metastases and Survival in Differentiated Thyroid Carcinoma. <i>Thyroid</i> , 2017, 27, 915-922.	4.5	7
114	Young Age and Male Sex Are Predictors of Large-Volume Central Neck Lymph Node Metastasis in Clinical NO Papillary Thyroid Microcarcinomas. <i>Thyroid</i> , 2017, 27, 1285-1290.	4.5	73
115	Association between thyroid autoimmunity and <i>Helicobacter pylori</i> infection. <i>Korean Journal of Internal Medicine</i> , 2017, 32, 309-313.	1.7	28
116	Low Prevalence of Somatic TERT Promoter Mutations in Classic Papillary Thyroid Carcinoma. <i>Endocrinology and Metabolism</i> , 2016, 31, 100.	3.0	16
117	Thyrotoxic Periodic Paralysis and Polymorphisms of the <i>ADRB2</i> , <i>AR</i> , and <i>GABRA3</i> Genes in Men with Graves Disease. <i>Endocrinology and Metabolism</i> , 2016, 31, 142.	3.0	4
118	Usefulness of Measuring Thyroid Stimulating Antibody at the Time of Antithyroid Drug Withdrawal for Predicting Relapse of Graves Disease. <i>Endocrinology and Metabolism</i> , 2016, 31, 300.	3.0	24
119	Metformin blocks progression of obesity-activated thyroid cancer in a mouse model. <i>Oncotarget</i> , 2016, 7, 34832-34844.	1.8	28
120	Molecular Diagnosis Using Residual Liquid-Based Cytology Materials for Patients with Nondiagnostic or Indeterminate Thyroid Nodules. <i>Endocrinology and Metabolism</i> , 2016, 31, 586.	3.0	15
121	Development of Tracheoesophageal Fistula after the Use of Sorafenib in Locally Advanced Papillary Thyroid Carcinoma: a Case Report. <i>International Journal of Thyroidology</i> , 2016, 9, 210.	0.1	4
122	Clinicopathological Implications of the BRAFV600E Mutation in PTC with Concurrent Hashimoto Thyroiditis. <i>International Journal of Thyroidology</i> , 2016, 9, 29.	0.1	0
123	Impact of Reclassification on Thyroid Nodules with Architectural Atypia: From Non-Invasive Encapsulated Follicular Variant Papillary Thyroid Carcinomas to Non-Invasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features. <i>PLoS ONE</i> , 2016, 11, e0167756.	2.5	22
124	Comparison of Thyroglobulin Measurements Using Three Different Immunoassay Kits: A BRAMHS Tg-Plus RIA Kit, a BRAMHS hTg Sensitive Kryptor Kit, and a Beckman Coulter ACCESS Immunoassay Kit. <i>Endocrinology and Metabolism</i> , 2016, 31, 462.	3.0	9
125	Clinicopathological Features Associated With the Prognosis of Patients With Adrenal Cortical Carcinoma. <i>Medicine (United States)</i> , 2016, 95, e3736.	1.0	13
126	Early prognostic factors at the time of diagnosis of bone metastasis in patients with bone metastases of differentiated thyroid carcinoma. <i>European Journal of Endocrinology</i> , 2016, 175, 165-172.	3.7	33



#	ARTICLE	IF	CITATIONS
127	Changing trends in the clinicopathological features and clinical outcomes of medullary thyroid carcinoma. <i>Journal of Surgical Oncology</i> , 2016, 113, 152-158.	1.7	19
128	Dynamic risk stratification for medullary thyroid cancer according to the response to initial therapy. <i>Endocrine</i> , 2016, 53, 174-181.	2.3	23
129	Usefulness of NRAS codon 61 mutation analysis and core needle biopsy for the diagnosis of thyroid nodules previously diagnosed as atypia of undetermined significance. <i>Endocrine</i> , 2016, 52, 305-312.	2.3	14
130	Genomic Alterations of Anaplastic Thyroid Carcinoma Detected by Targeted Massive Parallel Sequencing in a <i>BRAF</i> <sup>V600E</sup> Mutation-Prevalent Area. <i>Thyroid</i> , 2016, 26, 683-690.	4.5	66
131	Features Predictive of Distant Metastasis in Papillary Thyroid Microcarcinomas. <i>Thyroid</i> , 2016, 26, 161-168.	4.5	91
132	Alpha lipoic acid inhibits proliferation and epithelial mesenchymal transition of thyroid cancer cells. <i>Molecular and Cellular Endocrinology</i> , 2016, 419, 113-123.	3.2	34
133	Metformin Is Associated with a Favorable Outcome in Diabetic Patients with Cervical Lymph Node Metastasis of Differentiated Thyroid Cancer. <i>European Thyroid Journal</i> , 2015, 4, 181-188.	2.4	25
134	Association between neck ultrasonographic findings and clinicopathological features in the follicular variant of papillary thyroid carcinoma. <i>Clinical Endocrinology</i> , 2015, 83, 968-976.	2.4	15
135	Clinical course and prognostic factors in patients with malignant pheochromocytoma and paraganglioma: A single institution experience. <i>Journal of Surgical Oncology</i> , 2015, 112, 815-821.	1.7	29
136	Lack of Associations between Body Mass Index and Clinical Outcomes in Patients with Papillary Thyroid Carcinoma. <i>Endocrinology and Metabolism</i> , 2015, 30, 305.	3.0	15
137	Understanding of Cancer Cell Metabolism and Thyroid Cancer. <i>International Journal of Thyroidology</i> , 2015, 8, 147.	0.1	0
138	Association between Serum Gamma-Glutamyl Transferase and Thyroid Cancer in an Ultrasonographically Screened Population. <i>Journal of Korean Thyroid Association</i> , 2015, 8, 75.	0.2	0
139	Sub-Classification of Lateral Cervical Lymph Node Metastasis in Papillary Thyroid Carcinoma by Pathologic Criteria. <i>PLoS ONE</i> , 2015, 10, e0133625.	2.5	11
140	Changes in the Pulmonary Function Test after Radioactive Iodine Treatment in Patients with Pulmonary Metastases of Differentiated Thyroid Cancer. <i>PLoS ONE</i> , 2015, 10, e0125114.	2.5	7
141	Thyroglobulin Level in Fine-Needle Aspirates for Preoperative Diagnosis of Cervical Lymph Node Metastasis in Patients with Papillary Thyroid Carcinoma: Two Different Cutoff Values According to Serum Thyroglobulin Level. <i>Thyroid</i> , 2015, 25, 410-416.	4.5	39
142	Negative Expression of CPSF2 Predicts a Poorer Clinical Outcome in Patients with Papillary Thyroid Carcinoma. <i>Thyroid</i> , 2015, 25, 1020-1025.	4.5	13
143	Recent Changes in the Clinical Outcome of Papillary Thyroid Carcinoma With Cervical Lymph Node Metastasis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 3470-3477.	3.6	45
144	Clinicopathological Significance of Minimal Extrathyroid Extension in Solitary Papillary Thyroid Carcinomas. <i>Annals of Surgical Oncology</i> , 2015, 22, 728-733.	1.5	89

#	ARTICLE	IF	CITATIONS
145	A cutoff value of basal serum calcitonin for detecting macroscopic medullary thyroid carcinoma. <i>Clinical Endocrinology</i> , 2015, 82, 598-603.	2.4	19
146	Reference interval for thyrotropin in a ultrasonography screened Korean population. <i>Korean Journal of Internal Medicine</i> , 2015, 30, 335.	1.7	22
147	Time Trends Analysis of Characteristics of Patients with Thyroid Cancer in a Single Medical Center. <i>Journal of Korean Thyroid Association</i> , 2014, 7, 159.	0.2	2
148	Current Status and Future Perspectives in Differentiated Thyroid Cancer. <i>Endocrinology and Metabolism</i> , 2014, 29, 217.	3.0	68
149	Solitary Skin Metastasis of Papillary Thyroid Carcinoma. <i>Endocrinology and Metabolism</i> , 2014, 29, 579.	3.0	9
150	Standardized Thyroid Cancer Mortality in Korea between 1985 and 2010. <i>Endocrinology and Metabolism</i> , 2014, 29, 530.	3.0	36
151	Inhibition of Tumorigenesis by the Thyroid Hormone Receptor $\beta$ in Xenograft Models. <i>Thyroid</i> , 2014, 24, 260-269.	4.5	41
152	Association Between Expression of X-Linked Inhibitor of Apoptosis Protein and the Clinical Outcome in a BRAF <sup>V600E</sup> -Prevalent Papillary Thyroid Cancer Population. <i>Thyroid</i> , 2014, 24, 689-694.	4.5	23
153	Differentiating the location of cervical lymph node metastasis is very useful for estimating the risk of distant metastases in papillary thyroid carcinoma. <i>Clinical Endocrinology</i> , 2014, 81, 593-599.	2.4	17
154	Modified dynamic risk stratification for predicting recurrence using the response to initial therapy in patients with differentiated thyroid carcinoma. <i>European Journal of Endocrinology</i> , 2014, 170, 23-30.	3.7	69
155	Effects of Low-Dose and High-Dose Postoperative Radioiodine Therapy on the Clinical Outcome in Patients with Small Differentiated Thyroid Cancer Having Microscopic Extrathyroidal Extension. <i>Thyroid</i> , 2014, 24, 820-825.	4.5	56
156	Low Levels of Serum Vitamin D3 Are Associated with Autoimmune Thyroid Disease in Pre-Menopausal Women. <i>Thyroid</i> , 2014, 24, 655-661.	4.5	71
157	NRAS Codon 61 Mutation Is Associated with Distant Metastasis in Patients with Follicular Thyroid Carcinoma. <i>Thyroid</i> , 2014, 24, 1275-1281.	4.5	67
158	Follicular and Hurthle cell carcinoma of the thyroid in iodine-sufficient area: retrospective analysis of Korean multicenter data. <i>Korean Journal of Internal Medicine</i> , 2014, 29, 325.	1.7	29
159	The effect of 5-aminoimidazole-4-carboxamide-ribonucleoside was mediated by p38 mitogen activated protein kinase signaling pathway in FRO thyroid cancer cells. <i>Korean Journal of Internal Medicine</i> , 2014, 29, 474.	1.7	4
160	Long-Term Consequence of Elevated Thyroglobulin in Differentiated Thyroid Cancer. <i>Thyroid</i> , 2013, 23, 58-63.	4.5	23
161	Thyroid hormone receptors and cancer. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2013, 1830, 3928-3936.	2.4	87
162	Diet-Induced Obesity Increases Tumor Growth and Promotes Anaplastic Change in Thyroid Cancer in a Mouse Model. <i>Endocrinology</i> , 2013, 154, 2936-2947.	2.8	55

#	ARTICLE	IF	CITATIONS
163	Positive Cytology Findings and a Negative Histological Diagnosis of Papillary Thyroid Carcinoma in the Thyroid: Is It a False-Positive Cytology or a Disappearing Tumor. <i>European Thyroid Journal</i> , 2013, 2, 203-10.	2.4	10
164	Reactivation of the Silenced Thyroid Hormone Receptor $\beta 2$ Gene Expression Delays Thyroid Tumor Progression. <i>Endocrinology</i> , 2013, 154, 25-35.	2.8	49
165	Obesity is a risk factor for thyroid cancer in a large, ultrasonographically screened population. <i>European Journal of Endocrinology</i> , 2013, 168, 879-886.	3.7	98
166	Papillary thyroid carcinoma arising from a thyroglossal duct cyst: a single institution experience. <i>Endocrine Journal</i> , 2013, 60, 665-670.	1.6	54
167	Long-Term Clinical Outcome of Differentiated Thyroid Cancer Patients with Undetectable Stimulated Thyroglobulin Level One Year After Initial Treatment. <i>Thyroid</i> , 2012, 22, 784-790.	4.5	58
168	SKI-606, an Src Inhibitor, Reduces Tumor Growth, Invasion, and Distant Metastasis in a Mouse Model of Thyroid Cancer. <i>Clinical Cancer Research</i> , 2012, 18, 1281-1290.	7.0	39
169	Time trend in tumour size and characteristics of anaplastic thyroid carcinoma. <i>Clinical Endocrinology</i> , 2012, 77, 459-464.	2.4	30
170	Alpha-lipoic acid induces sodium iodide symporter expression in TPC-1 thyroid cancer cell line. <i>Nuclear Medicine and Biology</i> , 2012, 39, 1275-1280.	0.6	17
171	Alpha-Lipoic Acid Decreases Iodine Uptake in the Rat Thyroid Cell Line FRTL-5. <i>Journal of Korean Thyroid Association</i> , 2012, 5, 39.	0.2	0
172	Association between STAT1 activity and BRAF mutations in papillary thyroid carcinomas. <i>Journal of Surgical Oncology</i> , 2012, 106, 719-723.	1.7	7
173	Basal STAT3 activities are negatively correlated with tumor size in papillary thyroid carcinomas. <i>Journal of Endocrinological Investigation</i> , 2012, 35, 413-8.	3.3	16
174	Four Cases of Malignant Pleural Effusion in Patients with Papillary Thyroid Carcinoma. <i>Endocrinology and Metabolism</i> , 2011, 26, 330.	3.0	4
175	Expression of X-linked Inhibitor of Apoptosis Protein in Neoplastic Thyroid Disorder. <i>Journal of Korean Medical Science</i> , 2011, 26, 1191.	2.5	4
176	Effects of different doses of radioactive iodine for remnant ablation on successful ablation and on long-term recurrences in patients with differentiated thyroid carcinoma. <i>Nuclear Medicine Communications</i> , 2011, 32, 954-959.	1.1	33
177	Adjuvant Radioactive Therapy after Reoperation for Locoregionally Recurrent Papillary Thyroid Cancer in Patients Who Initially Underwent Total Thyroidectomy and High-Dose Remnant Ablation. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 3695-3700.	3.6	33
178	The influence of the BRAF V600E mutation in thyroid cancer cell lines on the anticancer effects of 5-aminoimidazole-4-carboxamide-ribonucleoside. <i>Journal of Endocrinology</i> , 2011, 211, 79-85.	2.6	24
179	The Outcomes of First Reoperation for Locoregionally Recurrent/Persistent Papillary Thyroid Carcinoma in Patients Who Initially Underwent Total Thyroidectomy and Remnant Ablation. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 2049-2056.	3.6	105
180	Comparison of Different Staging Systems for Predicting Recurrence of Papillary Thyroid Carcinoma. <i>Endocrinology and Metabolism</i> , 2011, 26, 53.	3.0	10

#	ARTICLE	IF	CITATIONS
181	The Long-Term Clinical Outcome of Differentiated Thyroid Carcinoma Patients Who Initially Underwent Total Thyroidectomy and Remnant Ablation, and with Undetectable Stimulated Thyroglobulin Level One Year after Remnant Ablation. , 2011, , P3-656-P3-656.		0
182	Concurrent occurrence of medullary thyroid carcinoma and papillary thyroid carcinoma in the same thyroid should be considered as coincidental. Clinical Endocrinology, 2010, 72, 256-263.	2.4	59
183	Clinical Outcomes of Persistent Radioiodine Uptake in the Neck Shown by Diagnostic Whole Body Scan in Patients with Differentiated Thyroid Carcinoma after Initial Surgery and Remnant Ablation. Clinical Endocrinology, 2010, 73, 257-63.	2.4	4
184	Postoperative Findings of the Cytological Diagnosis of Follicular Neoplasm or HÃ¼rthle Cell Neoplasm and the Risk of Malignancy. Endocrinology and Metabolism, 2010, 25, 316.	3.0	4
185	Empiric High-Dose 131-Iodine Therapy Lacks Efficacy for Treated Papillary Thyroid Cancer Patients with Detectable Serum Thyroglobulin, but Negative Cervical Sonography and 18F-Fluorodeoxyglucose Positron Emission Tomography Scan. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 1169-1173.	3.6	48
186	Effects of Î±-lipoic Acid on Differentiation of Thyroid Cancer Cells. Journal of Korean Endocrine Society, 2010, 25, 28.	0.1	0
187	Response: Effects of Î±-lipoic Acid on Differentiation of Thyroid Cancer Cells. Endocrinology and Metabolism, 2010, 25, 246.	3.0	0
188	Factors Influencing Peripheral Conversion of Thyroxine to Tri-Iodothyronine in Athyreotic Individuals during Levothyroxine Replacement. Endocrinology and Metabolism, 2010, 25, 119.	3.0	0
189	Coexistence of chronic lymphocytic thyroiditis is associated with lower recurrence rates in patients with papillary thyroid carcinoma. Clinical Endocrinology, 2009, 71, 581-586.	2.4	151
190	Redifferentiation Therapy with 13-cis Retinoic Acids in Radioiodine-Resistant Thyroid Cancer. Endocrine Journal, 2009, 56, 105-112.	1.6	45
191	Clinical Characteristics of Primary Thyroid Lymphoma in Koreans. Endocrine Journal, 2009, 56, 399-405.	1.6	68
192	Effects of Peroxisome Proliferator-Activated Receptor (PPAR) Delta on the Growth and Invasion of a Thyroid Cancer Cell Line. Journal of Korean Endocrine Society, 2009, 24, 25.	0.1	0
193	Prognostic parameters for recurrence of papillary thyroid microcarcinoma. BMC Cancer, 2008, 8, 296.	2.6	93
194	Change of Serum Antithyroglobulin Antibody Levels Is Useful for Prediction of Clinical Recurrence in Thyroglobulin-Negative Patients with Differentiated Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 4683-4689.	3.6	179
195	A Case of Carcinoma Showing Thymus-Like Differentiation (CASTLE) in the Thyroid. Journal of Korean Endocrine Society, 2008, 23, 272.	0.1	2
196	Effects of Simvastatin on the Growth and Invasion of Anaplastic Thyroid Cancer Cells Lines. Journal of Korean Endocrine Society, 2008, 23, 238.	0.1	1
197	CAG Repeats in the Androgen Receptor Polymorphism do not Correlate with Thyrotoxic Periodic Paralysis. Journal of Korean Endocrine Society, 2008, 23, 117.	0.1	3
198	Genomic alterations of anaplastic thyroid carcinoma detected by targeted massive parallel sequencing of a BRAFV600E mutation-prevalent area. Endocrine Abstracts, 0, , .	0.0	1

#	ARTICLE	IF	CITATIONS
199	The long-term clinical outcome of differentiated thyroid cancer patients with undetectable stimulated thyroglobulin level at one year after initial treatment. Thyroid, 0, , 120328072216008.	4.5	0
200	Clinical usefulness of dynamic risk stratification in medullary thyroid cancer. Endocrine Abstracts, 0, , .	0.0	0